Microsurgery for intracranial arteriovenous malformation: Long-term outcomes in 445 patients

Qingqing Ren*, Min He*, Yunhui Zeng, Zhiyong Liu, Hao Liu, Jianguo Xu*

Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, People’s Republic of China

* These authors contributed equally to this work.
* jgx_2015@163.com

Abstract

Background
The management of intracranial arteriovenous malformations (AVMs) poses challenges to the cerebrovascular specialists.

Objective
To review the long-term outcomes of intracranial AVMs treated with microsurgical resections.

Methods
We performed a retrospective review of 445 patients with intracranial AVMs treated in our hospital from January 1st, 2008 to December 31st, 2014. The extracted data included demographic characteristics, clinical presentations, Spetzler-Martin (SM) grades, Supplemented Spetzler-Martin (SM-Supp) Grades, treatment modalities, long-term outcomes, and obliteration rates. Outcome was assessed with a post-operative modified Rankin Scale (mRS) score at the last follow-up visit.

Results
Of the 445 patients treated with microsurgery, 298 (67.0%) patients initially presented with hemorrhage. Based on the SM grading system, the patients were graded as follows: 83 (18.6%) Grade I, 156 (35.1%) Grade II, 132 (29.7%) Grade III, 61 (13.7%) Grade IV and 13 (2.9%) Grade V. Overall, 344 (77.3%) patients had a favorable outcome (mRS score of 0–2). The favorable outcome for Grade I and II were 92.8% and 85.9%, respectively, sharply reducing to 52.5% in patients with Grade IV and 15.4% in patients with Grade V AVMs. 388 (87.2%) patients achieved complete obliteration of the AVMs. Of the 63 (14.2%) patients who experienced recurrent hemorrhage, the frequency of rehemorrhage was highest in Grade V patients (77.0%), dropping to 3.6% and 3.8% in patients with Grade I and II lesions, respectively. Permanent neurological deficits occurred in 66 (14.8%) patients and death in 35
(7.9%) patients. There was no difference of AUROC values between SM grading system and SM-supp grading system (0.726 and 0.734, respectively, p = .715).

**Conclusion**

The Spetzler-Martin grading system is a simple and effective method to estimate the risk of surgery and to evaluate the prognosis. Microsurgical resection for AVMs depends on the SM grades, and the morbidity-mortality rate increases with an increasing SM grade.

**Introduction**

Intracranial arteriovenous malformations (AVMs) are abnormalities of the intracranial vessels that compose tortuous arteries and veins, and lack an intervening capillary bed. AVMs are the most common type of intracranial vascular malformations, and the leading cause of nontraumatic intracerebral hemorrhages in young people less than 35 years old. The incidence of AVMs in unselected population is about 1 per 100,000 per year. AVMs account for 1% to 2% of all strokes, 3% of strokes in young adults, and 9% subarachnoid hemorrhages, and response for 4% of all primary intracerebral hemorrhages, but as much as one third in young adults. The Most common clinical presentations of AVMs are intracranial hemorrhage and seizures, and typically presented before the age of 40 years old. Focal neurologic deficits seem to occur in 1% to 40% of patients with intracranial AVMs, which can be transient, persistent or progressive. The average yearly risk for first hemorrhage is between 2% and 3%, while the rate of hemorrhage was 2.2% for unruptured AVMs and 4.5% for ruptured AVMs, but the risk of recurrent hemorrhage may be as high as 34% in the first year. Interventions including endovascular embolization techniques, stereotactic radiosurgery and microsurgery, have made great advances over the past decade, allowing effective multidisciplinary treatment of arteriovenous malformations. Nevertheless, the morbidity is as high as 53% to 81%, and the mortality ranges from 10% to 30%, although some data suggest that the mortality rate may be lower.

The management of intracranial arteriovenous malformations (AVMs) poses challenges to the cerebrovascular specialists. Microsurgical resections remain the most effective and immediate treatment for AVMs. Here we report a cohort of 450 patients with AVMs microsurgery resections in a single center over the past decade. We reviewed the long-term outcomes of these patients to evaluate the efficacy and safety of microsurgery resections for intracranial AVMs.

**Methods**

**Patient population and data collection**

With the approval of West China Hospital Institutional Ethical Review Board of Sichuan University, we undertook a retrospective review of our hospital database for all the patients diagnosed of intracranial AVMs who were treated with microsurgical resections during the period of January 1st, 2008 and December 31st, 2014. Written informed consent was obtained from each participating patient. Patients with any type of intracranial vascular malformations beyond AVMs as arteriovenous fistulas, vein of Galen malformations, or spinal vascular malformations were excluded from the analysis. A total of 445 patients were identified and patients baseline demographic, clinical, angiographic data were collected. The Spetzler-Martin
(SM) grade was applied to all patients when admitted to the hospital to assess surgical risk,[16] and the Supplemented Spetzler-Martin (SM-Supp) grade was accessed retrospectively.[17] The duration of follow-up was noted, at the end of the follow-up (death time or on July 1st, 2016), a modified Rankin Scale (mRS) score was assigned and documented.[18]

Surgical technique

When a patient was admitted to the hospital, the process of selecting the best therapy included microsurgery, endovascular therapy, and/or radiosurgery was made by a trained cerebrovascular neurosurgeon. The medical treatment decision was made based on both physician recommendations and patient preference. The desired goal of the treatment was permanently eliminating the AVM and preserving neurological functions. Assessment of AVM obliteration was determined by postoperative angiography.

Some patients with ruptured AVMs who were sent to the Emergency department received craniotomy and removal of hematoma prior to microsurgical resection. A portion of patients with planned staged treatment of the AVM underwent multimodality treatment with embolization or radiosurgery followed by microsurgery. Some patients received this procedure as a preoperative measure. However, a small group of patients was recommended for radiosurgery with/without endovascular treatment for residual AVMs after microsurgery.

Statistical analysis

Statistical analysis was performed with Stata version 14.0 (StataCorp, College Station, Texas). Statistical analysis for categorical variables was performed with chi-square test or the Fisher exact test, and comparisons between mean values of continuous variables were performed with a t-test. Univariate analysis was used to test covariates predictive of postoperative complications. All multivariable models included adjustment for the duration of follow-up (log transformed time), which influenced final mRS assessments. The areas under the Receiver operating characteristic (ROC) curves were compared for accuracy in predicting change in mRS score. An area under the ROC curve of 1.0 indicates perfect discrimination, whereas an area of 0.5 indicates no discrimination. Generally, an area under the ROC curve of 0.70 or more is considered a clinically useful predictive model. Any p values of ≤ 0.05 were considered statistically significant.

Results

Baseline characteristics

A cohort consisted of 445 patients who were treated with intracranial AVMs microsurgery in our hospital from 1st January 2008 to 31st December 2014. Table 1 provides a summary of baseline characteristics of the cohort. Patients ranged in age from 1 year to 78 years, with an average age of 32 years (±16 years). There were 285(64.0%) males and 160(36.0%) females in the study group. 298(67.0%) patients initially presented with hemorrhage, 82(18.4%) patients complained of headache without hemorrhage, and 63(14.2%) presented with seizures. Some other presenting symptoms included visual disturbance, ataxia, hemiplegic paralysis, weakness, coma and altered mental status. 39(8.8%) patients were incidentally discovered without any symptoms. The AVM location was lobar in 320(71.9%), deep supratentorial in 67(15.1%), and cerebellar in 58(13.0%) of the cases.

236(53.0%) of the AVMs nidus size were smaller than 3cm in diameter, 155(34.8%) were between 3-6cm, and 54(12.1%) were larger than 6cm in diameter, with an average of 3.3cm (±1.8cm). 186(41.8%) of the AVMs had deep venous drainage, and 40(9.0%) associated with
an aneurysm either on a flow-related artery or an intracranial location. Eloquence of adjacent brain was considered in 206(46.3%) cases. Based on the SM grading system (Table 2) for AVMs, there were 83(18.6%) Grade I lesions, 156(35.1%) Grade II lesions, 132(29.7%) Grade III lesions, 61(13.7%) Grade IV lesions and 13(2.9%) Grade V lesions (Table 3).

A total of 207(46.5%) patients were aged between 20 and 40 years, with 107(24.1%) younger than 20 years and 131(29.4%) older than 40 years. 298(67.0%) patients had intracranial hemorrhage which indicated rupture of the AVMs, while 99(22.2%) were assessed as diffuse AVMs. According to the SM-Supp grading system (Table 2), 11(2.5%), 34(7.6%), 123(27.6%), 130

Table 1. Baseline characteristics of all patients.

| Parameters       | Variable     | Patients No. (%) |
|------------------|--------------|------------------|
| Sex              | Male         | 285(64.0)        |
|                  | Female       | 160(36.0)        |
| Age              | Mean: 32(+16.0) years |               |
|                  | Range: 1–78 years |                |
| Presentation     | Hemorrhage   | 298(67.0)        |
|                  | Seizure      | 63(14.2)         |
|                  | Headache     | 82(18.4)         |
|                  | Incidental   | 39(8.8)          |
| Location         | Lobar        | 320(71.9)        |
|                  | Deep supratentorial | 67(15.1)     |
|                  | Cerebellar   | 58(13.0)         |

Table 2. Points of variables according to Spetzler-Martin grading scale and supplementary Spetzler-Martin grading scale.

| Variables        | Spetzler-Martin Grading | Supplementary Spetzler-Martin Grading |
|------------------|-------------------------|--------------------------------------|
| Size, cm         |                         |                                      |
| <3               | 1                       | 1                                    |
| 3–6              | 2                       | 2                                    |
| >6               | 3                       | 3                                    |
| Venous drainage  |                         |                                      |
| Superficial      | 0                       | 0                                    |
| Deep             | 1                       | 1                                    |
| Eloquence        |                         |                                      |
| No               | 0                       | 0                                    |
| Yes              | 1                       | 1                                    |
| Age, y           |                         |                                      |
| <20              | 1                       |                                      |
| 20–40            | 2                       |                                      |
| >40              | 3                       |                                      |
| Bleeding         |                         |                                      |
| Yes              | 0                       |                                      |
| No               | 1                       |                                      |
| Compactness      |                         |                                      |
| Yes              | 0                       |                                      |
| No               | 1                       |                                      |
| Total            | 5                       | 10                                   |

https://doi.org/10.1371/journal.pone.0174325.t001

https://doi.org/10.1371/journal.pone.0174325.t002
(29.2%), 69(15.5%), 52(11.7%), 20(4.5%), 4(0.9%), 2(0.5%) of the cases were classified as score 2–10, respectively (Table 3).

Clinical features and outcomes

Among all the 445 patients, 29(6.5%) underwent preoperative endovascular embolization of the AVMs, whereas 22(4.9%) had a single Gamma Knife radiation procedure prior to surgery, and Stereotactic radiosurgery (SRS) was performed on 5(1.1%) patients. Additionally, 36 (8.1%) patients received craniotomy and removal of hematoma at the Emergency department.
while 19(4.3%) had external ventricular drainage to decrease the intracranial pressure. Overall, 334(75.1%) patients underwent microsurgery resections only.

The follow-up time from completeness of surgery ranged from 1 day to 8.5 years, with a median of 4.6 years (±2.2 years). Postoperative cerebral angiogram including digital subtraction angiography (DSA), computed tomography angiography (CTA) and magnetic resonance angiography (MRA) was performed to assess the obliteration status. Of all the 445 patients, 388(87.2%) achieved complete obliteration of the AVMs, while 57(12.8%) had partial obliteration with residual arteriovenous shunting. Among the 57 patients with incomplete resections, 38(66.7%) underwent Gamma Knife radiation, 13(22.8%) underwent endovascular embolization, 2(3.5%) received repeat microsurgical resections, and 4(7.0%) had conservative management during the observational period.

The 1- and 5-year overall survival rates for patients with microsurgery were 95.3% and 92.1%, respectively. AVMs resulted in death in 35(7.9%) patients at the end of the follow-up time. 23(65.7%) of the 35 patients died of cerebral hernia caused by acute severe hemorrhage or re-hemorrhage, 7(20.0%) for infections (intracranial infection, pneumonia, fungi or bacteremia), 3(8.6%) for multiple organ failures, and 2(5.7%) gave up for financial conditions. Permanent neurological deficits occurred in 66(14.8%) patients, including 22 cases of hemiparesis, 6 of hemiplegia, 11 of aphasia, 5 of ability, 13 of hydrocephalus, 3 of vegetative state and 6 local neurological dysfunctions. 11 of the 13 patients with hydrocephalus underwent postoperative ventriculoperitoneal shunt placement. Postoperative seizures occurred in 19 (4.3%) patients and all under control after taking antiepileptic medication. 63(14.2%) patients experienced reoccurred hemorrhage.

On presentation, 344(77.3%) patients had a favorable outcome (mRS score of 0–2).[19] The mRS of the entire cohort was as follows: 152(34.2%) patients had mRS of 0, 113(25.4%) had mRS of 1, 79(17.7%) had mRS of 2, 31(7.0%) had mRS of 3, 22(4.9%) had mRS of 4, 13(2.9%) had mRS of 5, and 35(7.9%) had mRS of 6. Univariable logistic regression analysis identified AVM size (P < .001), deep venous drainage (P < .001), age (P < .001) and diffuse nidus (P = .005) as significant predictors of poor outcome (mRS score >2) (Table 4). Whereas eloquence (P = .235) and unruptured presentation (P = .265) were not associated with poor outcome. In multivariate analysis, predictors of poor outcome (Table 5) were deep venous drainage (OR 2.46, 95% CI 1.40–4.35; p = .002), eloquence (OR 7.77, 95% CI 3.64–16.59; p < .001), age (OR 1.12, 95% CI 1.09–1.16; p < .001), unruptured AVMs (OR 2.51, 95% CI 1.27–4.97; p = .008) and diffuse nidus (OR 4.18, 95% CI 2.05–8.54; p < .001). The area under the ROC curve of SM grading system (0.726) was slightly lower than that of SM-supp grading system (0.734), but there was no significant difference between them (p = .715) (Fig 1).

The SM grading system accurately correlated with long-term outcomes. The favorable outcome for Grade I and II were 92.8% and 85.9%, respectively, sharply reducing to 52.5% in

| Variable  | OR  | 95% CI  | P value |
|-----------|-----|---------|---------|
| Size      | 1.58| 1.39    | 1.80    | 0.000  |
| Drainage  | 2.68| 1.69    | 4.21    | 0.000  |
| Eloquence | 1.31| 0.84    | 2.04    | 0.235  |
| Age       | 1.08| 1.06    | 1.10    | 0.000  |
| Unrupture | 1.30| 0.82    | 2.06    | 0.265  |
| Diffuse   | 2.04| 1.25    | 3.35    | 0.005  |

OR, odds ratio; CI, confidence interval

https://doi.org/10.1371/journal.pone.0174325.t004
patients with Grade IV and 15.4% in patients with Grade V AVMs (P = .004). The mortality rate of patients with Grade I AVMs was 0, increasing to 38.5% in patients with Grade V AVMs (P < .001). The frequency of rehemorrhage was highest in Grade V patients (77.0%), dropping to 3.6% and 3.8% in patients with Grade I and II lesions, respectively (P < .001).

**Discussion**

**General characteristics**

The incidence of intracranial AVMs is 1–1.4 cases per 100,000 person-years, and both sexes are affected equally.[2, 5, 20–28] The population of our group consisted of 285 males and 160
females, giving a 1.8:1 male preponderance, which is approximately similar to a Chinese population of 2086 patients with AVMs reported by Zhao et al in 2005[29]. The annual hemorrhage rate for unruptured and untreated brain AVMs is 2% to 4%, and the incidence of patients with brain AVMs presenting with intracranial hemorrhage is approximately 38% to 71%.[4, 7, 8, 20, 21, 27, 30–34] In our cohort, 67% of the patients presented with intracranial hemorrhage, and our result falls within this range. Based on our results, intracranial AVMs are typically diagnosed before the age of 40 years (70.6%), with hemorrhage (67.0%), headache (18.4%) and seizures (14.2%) as the presenting symptoms leading to the diagnosis.

Microsurgery management and outcomes
AVMs were initially described by Luschka in 1854 and Virchow in 1863.[35, 36] Giordano performed the first open-surgery for an AVM and Péan performed the first surgically elimination of an AVM in 1889.[37] The treatment of intracranial AVMs including microsurgical resections, radiotherapy and endovascular embolization has made great advance over the past decades,[12, 38–44] but the management of intracranial AVMs remains controversial and challenging. The main treatment aim is to achieve complete angiographic obliteration of the AVMs, while preserving neurological functions.[9] Advantages of microsurgery are high rate of complete obliteration, and that it is the most time-tested and immediate treatment.[15, 39]

A systematic review and meta-analysis conducted by Beijnum and colleagues in 2011 reported that AVM obliteration was achieved in 96% (range 0% to 100%) of patients, with permanent neurological deficits or death occurring in a median 7.4% (range from 0% to 40%) of patients after microsurgery.[44] A meta-analysis comprising 2452 patients from 25 studies published between January 1990 and December 2000 showed a postoperative mortality of 3.3%, a permanent postoperative morbidity of 8.6%, varying from 1.5% to 18.7%, with postoperative angiography confirming a total excision of the AVM in 97% of the cases, varying from 91% to 100%.[45] Theofanis et al reported 264 patients treated with microsurgery and showed rates of permanent surgical morbidity and mortality of 1.9% and 2.7%, respectively, with an obliteration rate of 100%.[46] We presented a cohort comprising 445 patients treated with microsurgical resections in a large single center, and illustrated a permanent postoperative morbidity of 14.8% and a mortality of 7.9%. Even minor changes such as hydrocephalus or a small visual field deficit were assessed and rated as a deficit. All deaths were in patients who presented with hemorrhage and underwent urgent surgery, with a Glasgow coma scale of 7 or lower pre- or post-operation. Because ruptured brain AVMs presumably have a higher hemorrhage risk (4.5–34%) than unruptured ones (0.9–8%),[8] a high rate of hemorrhage presentation (67%) led to a high rate of rehemorrhage (14.2%), which both contributed to the disability and death, although presentation with AVM hemorrhage is an underappreciated predictor of outcome after microsurgical resection.[47]

A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) is a multicentre, non-blinded, randomized trial aimed to evaluate the risk of patients with an unruptured brain AVM treated with medical management alone compared to medical management with interventional therapy.[48] The ARUBA trial was started on April 4, 2007, and was halted on April 15, 2013 after an interim analysis showed that medical management alone is superior to medical management with interventional therapy (microsurgery, embolization, or radiosurgery) for the prevention of death or stroke in patients with unruptured brain AVMs followed up for 33 months. However, the results of ARUBA have provoked severe debates over concerns for weaknesses in study design, treatment modality, follow-up length, and external validity.[49–57] Of 223 patients with interim analysis when ARUBA was halted, 114 assigned to interventional therapy and 109 to medical management, only 18 patients were treated with
It’s criticized that only 5 patients treated surgically alone when 76 patients had an SM score of 1 or 2. There were 147 patients with unruptured brain AVMs in our study, and 89 (60.5%) patients with SM Grade I or II received microsurgical resections and 78 (87.6%) developed good outcome with an mRS score of 0–2. However, a pragmatic randomized controlled trial started on March 25, 2014 is currently recruiting participants. Treatment of Brain Arteriovenous Malformations Study (TOBAS) is a study including two randomized controlled trials and a registry to test the risk of death or debilitating stroke for unruptured AVMs treated with medical management compared to interventional therapy and to test if endovascular treatment can improve the safety and efficacy of surgery or radiation therapy.

Spetzler-Martin grading and supplemented Spetzler-Martin grading system

In 1986, Spetzler and Martin introduced a classification system based on lesion size, location, and venous drainage to evaluate surgical risk for intracranial AVMs (Table 2). Spetzler and Ponce introduced a simplified and consolidated 3-tier classification for AVMs: class A, including the Grade I and II Spetzler-Martin AVMs; class B, including the Grade III Spetzler-Martin AVMs; and class C, including the Grade IV and V Spetzler-Martin AVMs. Many other grading scales have been proposed, however, Spetzler-Martin five-points scale is the most popular and widely used grading system. Microsurgical resection of Grade I-II AVMs offers an immediate cure with very low procedural morbidity, while Grade IV–V AVMs are associated with unacceptably high morbidity and mortality rates, and the morbidity-mortality rate increases with an increasing Spetzler-Martin’s grade. Experience suggested that many important factors were interrelated. In 2010, Lawton et al introduced a supplementary grading system including additional variables such as patient age, hemorrhagic presentation, nidal diffuseness, and deep perforating arterial supply. The supplementary grading system is a better predictor of neurologic outcomes after AVM surgery than the Spetzler-Martin grading system, and an SM-Supp grade of 6 is a cutoff or boundary for decision of microsurgery.

In our series, the AUROC value for the SM-Supp system was a little better than for the SM system alone (AUROC = 0.734 vs 0.726; P = .715; Fig 1), which demonstrates that there is no difference in predictive accuracy between SM system and SM-Supp system. Female sex is another factor affects the outcomes of the microsurgery in the multivariate analysis, nevertheless, it is not included in SM-supp grading system. The SM-Supp model performed equally well in predicting risk of microsurgery, although Kim et al reported that the SM-Supp model was certified performing better than current prediction models.

Limitations

Limitations include that the study is a retrospective review in a single-center, and the recall bias. The surgeries were operated by different neurosurgeons.

Conclusion

The Spetzler-Martin grading system is a simple and effective method to estimate the risk of surgery and to evaluate the prognosis. Microsurgical resection for AVMs depends on the SM grades, and the morbidity-mortality rate increases with an increasing SM grade.
Author Contributions

Conceptualization: QR MH JX.
Data curation: QR MH YZ.
Formal analysis: QR MH YZ.
Funding acquisition: JX.
Investigation: QR MH ZL.
Methodology: QR MH ZL.
Project administration: JX.
Resources: HL JX.
Software: QR MH YZ.
Supervision: JX.
Validation: YZ HL.
Visualization: ZL.
Writing – original draft: QR.
Writing – review & editing: HL JX.

References

1. Ruiz-Sandoval JL, Cantu C, Barinagarrementeria F. Intracerebral hemorrhage in young people: analysis of risk factors, location, causes, and prognosis. Stroke; a journal of cerebral circulation. 1999; 30 (3):537–41.
2. Al-Shahi R, Bhattacharyya JJ, Currie DG, Papanastassiou V, Ritchie V, Roberts RC, et al. Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS). Stroke; a journal of cerebral circulation. 2003; 34(5):1163–9.
3. Al-Shahi R, Warlow C. A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults. Brain: a journal of neurology. 2001; 124(Pt 10):1900–26.
4. da Costa L, Wallace MC, Ter Brugge KG, O’Kelly C, Willinsky RA, Tymianski M. The natural history and predictive features of hemorrhage from brain arteriovenous malformations. Stroke; a journal of cerebral circulation. 2009; 40(1):100–5.
5. Arteriovenous malformations of the brain in adults. The New England journal of medicine. 1999; 340 (23):1812–8. https://doi.org/10.1056/NEJM199906103402307 PMID: 10362826
6. Graf CJ, Perret GE, Tomer JC. Bleeding from cerebral arteriovenous malformations as part of their natural history. Journal of neurosurgery. 1983; 58(3):331–7. https://doi.org/10.3171/jns.1983.58.3.0331 PMID: 6827317
7. Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. Journal of neurosurgery. 2013; 118(2):437–43. https://doi.org/10.3171/2012.10.JNS121280 PMID: 23198804
8. Stapf C, Mast H, Sciacca RR, Choi JH, Khaw AV, Connolly ES, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology. 2006; 66(9):1350–5. https://doi.org/10.1212/01.wnl.0000210524.68507.87 PMID: 16682666
9. Fleetwood IG, Steinberg GK. Arteriovenous malformations. Lancet (London, England). 2002; 359 (9309):863–73.
10. Perret G, Nishioka H. Report on the cooperative study of intracranial aneurysms and subarachnoid hemorrhage. Section VI. Arteriovenous malformations. An analysis of 545 cases of cranio-cerebral arteriovenous malformations and fistulae reported to the cooperative study. Journal of neurosurgery. 1966; 25(4):467–90. PMID: 5925721
11. Hartmann A, Mast H, Mohr JP, Koennecke HC, Osipov A, Pile-Spellman J, et al. Morbidity of intracranial hemorrhage in patients with cerebral arteriovenous malformation. Stroke; a journal of cerebral circulation. 1998; 29(5):931–4.
12. Plasencia AR, Santillan A. Embolization and radiosurgery for arteriovenous malformations. Surgical neurology international. 2012; 3(Suppl 2):S90–s104. https://doi.org/10.4103/2152-7806.95420 PMID: 22826821

13. Ogilvy CS, Stieg PE, Awad I, Brown RD Jr., Kondziolka D, Rosenwasser R, et al. Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Circulation. 2001; 103(21):2644–57. PMID: 11382737

14. Peschillo S, Caporlingua A, Colonnese C, Guidetti G. Brain AVMs: an endovascular, surgical, and radiosurgical update. TheScientificWorldJournal. 2014; 2014:834931. https://doi.org/10.1155/2014/834931 PMID: 25401156

15. Serrone J, Zuccarello M. The role of microsurgical resection and radiosurgery for cerebral arteriovenous malformations. Methodist DeBakey cardiovascular journal. 2014; 10(4):240–4. https://doi.org/10.14797/mdcj-10-4-240 PMID: 25624979

16. Speizler RF, Martin NA. A proposed grading system for arteriovenous malformations. 1986. Journal of neurosurgery. 2008; 108(1):186–93. PMID: 18173333

17. Lawton MT, Kim H, McCulloch CE, Mikhail B, Young WL. A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. Neurosurgery. 2010; 66(4):702–13; discussion 13. https://doi.org/10.1227/01.NEU.0000367555.16733.E1 PMID: 20190666

18. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke; a journal of cerebral circulation. 1988; 19(5):604–7.

19. Weisscher N, Vermeulen M, Roos YB, de Haan RJ. What should be defined as good outcome in stroke trials; a modified Rankin score of 0–1 or 0–2? Journal of neurology. 2008; 255(6):867–74. https://doi.org/10.1007/s00415-008-0796-8 PMID: 18338195

20. Abecasis LJ, Xu DS, Batjer HH, Bendok BR. Natural history of brain arteriovenous malformations: a systematic review. Neurosurgical focus. 2014; 37(3):E7. https://doi.org/10.3171/2014.6.FOCUS14250 PMID: 25175445

21. Brown RD Jr., Wiebers DO, Torner JC, O’Fallon WM. Frequency of intracranial hemorrhage as a presenting symptom and subtype analysis: a population-based study of intracranial vascular malformations in Olmsted County, Minnesota. Journal of neurosurgery. 1996; 85(1):29–32. https://doi.org/10.3171/jns.1996.85.1.0029 PMID: 8683279

22. Brown RD Jr., Wiebers DO, Torner JC, O’Fallon WM. Incidence and prevalence of intracranial vascular malformations in Olmsted County, Minnesota, 1965 to 1992. Neurology. 1996; 46(4):949–52. PMID: 8780070

23. Gabriel RA, Kim H, Sidney S, McCulloch CE, Singh V, Johnston SC, et al. Ten-year detection rate of brain arteriovenous malformations in a large, multiethnic, defined population. Stroke; a journal of cerebral circulation. 2010; 41(1):21–6.

24. Hillman J. Population-based analysis of arteriovenous malformation treatment. Journal of neurosurgery. 2001; 95(4):633–7. https://doi.org/10.3171/jns.2001.95.4.0633 PMID: 11596958

25. Jessurun GA, Kamphuis DJ, van der Zande FH, Nossent JC. Cerebral arteriovenous malformations in The Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clinical neurology and neurosurgery. 1993; 95(3):193–8. PMID: 8242961

26. Stapf C, Mast H, Sciaccia RR, Berenstein A, Nelson PK, Gobin YP, et al. The New York Islands AVM Study: design, study progress, and initial results. Stroke; a journal of cerebral circulation. 2003; 34(5):e29–33.

27. Berman MF, Sciaccia RR, Pile-Spellman J, Stapf C, Connolly ES Jr., Mohr JP, et al. The epidemiology of brain arteriovenous malformations. Neurosurgery. 2000; 47(2):389–96; discussion 97. PMID: 10942012

28. Heros RC, Korosue K, Diebold PM. Surgical excision of cerebral arteriovenous malformations: late results. Neurosurgery. 1990; 26(4):570–7; discussion 7–8. PMID: 2330077

29. Zhao J, Wang S, Li J, Qi W, Sui D, Zhao Y. Clinical characteristics and surgical results of patients with cerebral arteriovenous malformations. Surgical neurology. 2005; 63(2):156–61; discussion 61. https://doi.org/10.1016/j.surneu.2004.04.021 PMID: 15680660

30. Mast H, Mohr JP, Ospov A, Pile-Spellman J, Marshall RS, Lazar RM, et al. ‘Steal’ is an unestablished mechanism for the clinical presentation of cerebral arteriovenous malformations. Stroke; a journal of cerebral circulation. 1995; 26(7):1215–20.

31. Yamada S, Takagi Y, Nozaki K, Kikuta K, Hashimoto N. Risk factors for subsequent hemorrhage in patients with cerebral arteriovenous malformations. Journal of neurosurgery. 2007; 107(5):965–72. https://doi.org/10.3171/JNS-07/11/0965 PMID: 17977268
32. Hernesniemi JA, Dashti R, Juvela S, Vaart K, Niemela M, Laakso A. Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery. 2008; 63(5):823–9; discussion 9–31. https://doi.org/10.1227/01.NEU.0000330401.82582.5E PMID: 19005371

33. Kim H, Sidney S, McCulloch CE, Poon KY, Singh V, Johnston SC, et al. Racial/Ethnic differences in longitudinal risk of intracranial hemorrhage in brain arteriovenous malformation patients. Stroke; a journal of cerebral circulation. 2007; 38(9):2430–7.

34. Langer DJ, Lasner TM, Hurst RW, Flamm ES, Zager EL, King JT Jr.. Hypertension, small size, and deep venous drainage are associated with risk of hemorrhagic presentation of cerebral arteriovenous malformations. Neurosurgery. 1998; 42(3):481–6; discussion 7–9. PMID: 9526981

35. von LH. Die Adergeflechte des menschlichen Gehirnes: eine Monographie. G Reimer. 1855.

36. Virchow R. Handbuch der speziellen Pathologie und Therapie: Enke; 1856.

37. Yasargil M. Microneurosurgery: Thieme Classics. New York: NY: Thieme Medical Publishers; 1987.

38. Bendok BR, El Tecle NE, El Ahmadieh TY, Koht A, Gallagher TA, Carroll TJ, et al. Advances and innovations in brain arteriovenous malformation surgery. Neurosurgery. 2014; 74 Suppl 1:S60–73. https://doi.org/10.1227/NEU.0000000000000230 PMID: 28175885

39. Davies JM, Yanamadala V, Lawton MT. Comparative effectiveneess of treatments for cerebral arteriovenous malformations: trends in nationwide outcomes from 2000 to 2009. Neurosurgical focus. 2012; 33(1):E11. https://doi.org/10.3171/2012.5.FOCUS12107 PMID: 22746228

40. Hartmann A, Mast H, Mohr JP, Pile-Spellman J, Connolly ES, Sciaccia RR, et al. Determinants of staged endovascular and surgical treatment outcome of brain arteriovenous malformations. Stroke; a journal of cerebral circulation. 2005; 36(11):2431–5.

41. Hartmann A, Stapf C, Hofmeister C, Mohr JP, Sciaccia RR, Stein BM, et al. Determinants of neurological outcome after surgery for brain arteriovenous malformation. Stroke; a journal of cerebral circulation. 2000; 31(10):2361–4.

42. Ross J, Al-Shahi Salman R. Interventions for treating brain arteriovenous malformations in adults. The Cochrane database of systematic reviews. 2010(7):Cd003436. https://doi.org/10.1002/14651858.CD003436.pub3 PMID: 20614434

43. Rubin BA, Brunswick A, Riina H, Kondziolka D. Advances in radiosurgery for arteriovenous malformations of the brain. Neurosurgery. 2014; 74 Suppl 1:S50–8. https://doi.org/10.1227/NEU.0000000000000219 PMID: 28175847

44. van Beijnum J, van der Worp HB, Buis DR, Al-Shahi Salman R, Kappelle LJ, Rinkel GJ, et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. Jama. 2011; 306(18):2011–9. https://doi.org/10.1001/jama.2011.1632 PMID: 22068993

45. Castel JP, Kantor G. [Postoperative morbidity and mortality after microsurgical exclusion of cerebral arteriovenous malformations. Current data and analysis of recent literature]. Neuro-Chirurgie. 2001; 47(2–3 Pt 2):369–83. PMID: 11404718

46. Theoianis T, Chalouhi N, Dalayi R, Starke RM, Jabbour P, Rosenwasser RH, et al. Microsurgery for cerebral arteriovenous malformations: postoperative outcomes and predictors of complications in 264 cases. Neurosurgical focus. 2014; 37(3):E10. https://doi.org/10.3171/2014.7.FOCUS14160 PMID: 25175429

47. Lawton MT, Du R, Tran MN, Achrol AS, McCulloch CE, Johnston SC, et al. Effect of presenting hemorrhage on outcome after microsurgical resection of brain arteriovenous malformations. Neurosurgery. 2005; 56(3):485–93; discussion -93. PMID: 15730573

48. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overby JR, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet (London, England). 2014; 383(9917):614–21.

49. Russin J, Spetzler R. Commentary: The ARUBA trial. Neurosurgery. 2014; 75(1):E96–7. https://doi.org/10.1227/NEU.000000000000357 PMID: 24670633

50. Nerva JD, Mantovani A, Barber J, Kim LJ, Rockhill JK, Hallam DK, et al. Treatment outcomes of unruptured arteriovenous malformations with a subgroup analysis of ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)-eligible patients. Neurosurgery. 2015; 76(5):563–70; discussion70; quiz 70. https://doi.org/10.1227/NEU.0000000000000663 PMID: 25635891

51. Starke RM, Sheehan JP, Ding D, Liu KC, Kondziolka D, Crowley RW, et al. Conservative management or intervention for unruptured brain arteriovenous malformations. World neurosurgery. 2014; 82(5):e668–9. https://doi.org/10.1016/j.wneu.2014.07.001 PMID: 25053736

52. Warlow C. Management of brain arteriovenous malformations. Lancet (London, England). 2014; 383(9929):1632–3.
53. Al-Shahi Salman R. Management of brain arteriovenous malformations. Lancet (London, England). 2014; 383(9929):1633–4.

54. Solomon RA, Connolly ES Jr.. Management of brain arteriovenous malformations. Lancet (London, England). 2014; 383(9929):1634.

55. Lawton MT, Abla AA. Management of brain arteriovenous malformations. Lancet (London, England). 2014; 383(9929):1634–5.

56. Gross BA, Scott RM, Smith ER. Management of brain arteriovenous malformations. Lancet (London, England). 2014; 383(9929):1635.

57. Grasso G. The ARUBA study: what is the evidence? World neurosurgery. 2014; 82(3–4):e576.

58. Darsaut TE, Magro E, Gentric JC, Batista AL, Chaalala C, Roberge D, et al. Treatment of Brain AVMs (TOBAS): study protocol for a pragmatic randomized controlled trial. Trials. 2015; 16:497. https://doi.org/10.1186/s13063-015-1019-0 PMID: 26530856

59. Magro E, Gentric JC, Darsaut TE, Batista AL, Chaalala C, Roberge D, et al. [Treatment of brain AVMS (TOBAS): A randomized controlled trial and registry]. Neuro-Chirurgie. 2016.

60. Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. Journal of neurosurgery. 1986; 65(4):476–83. https://doi.org/10.3171/jns.1986.65.4.0476 PMID: 3760956

61. Spetzler RF, Ponce FA. A 3-tier classification of cerebral arteriovenous malformations. Clinical article. Journal of neurosurgery. 2011; 114(3):842–9. https://doi.org/10.3171/2010.8.JNS10663 PMID: 20932095

62. Brown RD Jr.. Simple risk predictions for arteriovenous malformation hemorrhage. Neurosurgery. 2000; 46(4):1024.

63. Malik GM, Pasqualin A, Ausman JI. A New Grading System for Cerebral Arteriovenous Malformations. In: Pasqualin A, Da Pian R, editors. New Trends in Management of Cerebro-Vascular Malformations: Proceedings of the International Conference Verona, Italy, June 8–12, 1992. Vienna: Springer Vienna; 1994. p. 328–32.

64. Shi YQ, Chen XC. A proposed scheme for grading intracranial arteriovenous malformations. Journal of neurosurgery. 1986; 65(4):484–9. https://doi.org/10.3171/jns.1986.65.4.0484 PMID: 3760957

65. Hollerhage HG, Zumkeller M, Dewenter KM. [Prognostic value of grading systems in cerebral arteriovenous malformations]. Neurochirurgia. 1990; 33(3):59–64. PMID: 2374635

66. Luessenhop AJ, Gennarelli TA. Anatomical grading of supratentorial arteriovenous malformations for determining operability. Neurosurgery. 1977; 1(1):30–5. PMID: 615949

67. Pasqualin A, Barone G, Cioffi F, Rosta L, Scienza R, Da Pian R. The relevance of anatomic and hemodynamic factors to a classification of cerebral arteriovenous malformations. Neurosurgery. 1991; 28(3):370–9. PMID: 2011218

68. Pellettieri L, Carlsson CA, Grevensten S, Norlen G, Uhlemann C. Surgical versus conservative treatment of intracranial arteriovenous malformations: a study in surgical decision-making. Acta neurochirurgica Supplementum. 1979; 29:1–86. PMID: 295571

69. Pertuiset B, Ancri D, Kinuta Y, Haisa T, Bordi L, Lin C, et al. Classification of supratentorial arteriovenous malformations. A score system for evaluation of operability and surgical strategy based on an analysis of 66 cases. Acta neurochirurgica. 1991; 110(1–2):6–16. PMID: 1882721

70. Tamaki N, Ebara K, Lin TK, Kuwamura K, Obara Y, Kanazawa Y, et al. Cerebral arteriovenous malformations: factors influencing the surgical difficulty and outcome. Neurosurgery. 1991; 29(6):856–61; discussion 61–3. PMID: 1758597

71. Steinmeier R, Schramm J, Muller HG, Fahibusch R. Evaluation of prognostic factors in cerebral arteriovenous malformations. Neurosurgery. 1989; 24(2):193–200. PMID: 2918970

72. Hollerhage HG, Dewenter KM, Dietz H. Grading of supratentorial arteriovenous malformations on the basis of multivariate analysis of prognostic factors. Acta neurochirurgica. 1992; 117(3–4):129–34. PMID: 1414513

73. Hamilton MG, Spetzler RF. The prospective application of a grading system for arteriovenous malformations. Neurosurgery. 1994; 34(1):2–6; discussion -7. PMID: 8121564

74. Kim H, Abla AA, Nelson J, McCulloch CE, Bervini D, Morgan MK, et al. Validation of the supplemented Spetzler-Martin grading system for brain arteriovenous malformations in a multicenter cohort of 1009 surgical patients. Neurosurgery. 2015; 76(1):25–31; discussion -2; quiz 2–3. https://doi.org/10.1227/NEU.0000000000000556 PMID: 25251197

75. Kim H, Pourmohamad T, Westbroek EM, McCulloch CE, Lawton MT, Young WL. Evaluating performance of the spetzler-martin supplemented model in selecting patients with brain arteriovenous malformation for surgery. Stroke; a journal of cerebral circulation. 2012; 43(9):2497–9.